Bhende Shubhangi, Barbolt Thomas, Rothenburger Stephen, Piccoli Leslie
ETHICON (Johnson & Johnson), Somerville, New Jersey 08876, USA.
Surg Infect (Larchmt). 2007 Jun;8(3):405-14. doi: 10.1089/sur.2005.061.
To evaluate the potential of synthetic surgical meshes (Marlex((R)) mesh [C.R. Bard, Inc., Murray Hill, NJ]; MYCROMESH PLUS [W.L. Gore and Associates, Inc., Flagstaff, AZ]; GYNECARE GYNEMESH Nonabsorbable PROLENE* Soft Mesh [Ethicon, Somerville, NJ]; and naturally derived surgical mesh materials (DermMatrix) [Carbon Medical Technologies, St. Paul, MN] and SURGISIS [Cook Surgical, Spencer, IN]) to serve as a nidus for microbial attachment and growth, thus exacerbating surgical site infection.
Meshes were implanted subcutaneously in mice and inoculated with 10(4) colony-forming units (cfu) of Staphylococcus aureus. Mice were euthanized four days later, and the implants were removed, homogenized, and cultured using a standard agar pour plate method to determine the number of viable bacteria that could be recovered from each implant.
The Marlex mesh and Gynecare Gynemesh PS were comparable and "neutral" to infection, the average number of bacteria recovered being 1.61 x 10(5) and 5.41 x 10(4) cfu, respectively. Mycromesh Plus, with its antibacterial coating, resulted in a reduction in the number of bacteria recovered, the average being 1.61 x 10(1) cfu. Naturally derived meshes were considered to potentiate infection on the basis of macroscopic observation of infection and significantly increased numbers of bacteria recovered from the implant: 1.84 x 10(8) cfu from DermMatrix and 3.17 x 10(7) cfu from Surgisis.
The synthetic meshes did not potentiate infection in this model, whereas the naturally-derived materials did. As this preclinical model was able to detect differences between different implant materials, it may have utility in assessing the infection potentiation properties of newly developed materials.
评估合成外科补片(Marlex®补片[C.R. Bard公司,新泽西州默里山];MYCROMESH PLUS[W.L. Gore & Associates公司,亚利桑那州弗拉格斯塔夫];GYNECARE GYNEMESH不可吸收PROLENE*柔软补片[Ethicon公司,新泽西州萨默维尔])以及天然来源的外科补片材料(DermMatrix[Carbon Medical Technologies公司,明尼苏达州圣保罗]和SURGISIS[Cook Surgical公司,印第安纳州斯宾塞])作为微生物附着和生长的病灶从而加剧手术部位感染的可能性。
将补片皮下植入小鼠体内,并用10⁴个金黄色葡萄球菌菌落形成单位(cfu)进行接种。四天后对小鼠实施安乐死,取出植入物,进行匀浆处理,并采用标准琼脂倾注平板法进行培养,以确定可从每个植入物中回收的活菌数量。
Marlex补片和GYNECARE GYNEMESH PS对感染的影响相当且呈“中性”,回收的细菌平均数量分别为1.61×10⁵ cfu和5.41×10⁴ cfu。带有抗菌涂层的MYCROMESH PLUS导致回收的细菌数量减少,平均为1.61×10¹ cfu。基于对感染的宏观观察以及从植入物中回收的细菌数量显著增加,天然来源的补片被认为会增强感染:DermMatrix为1.84×10⁸ cfu,SURGISIS为3.17×10⁷ cfu。
在该模型中,合成补片不会增强感染,而天然来源的材料会。由于这个临床前模型能够检测出不同植入材料之间的差异,它可能在评估新开发材料的感染增强特性方面具有实用性。